ClinicalTrials.gg
CompletedNCT04322149Updated Jun 28, 2023Results posted

Multiple Doses of AT-1501-A201 in Adults With ALS

A Phase 2 interventional study of AT-1501 in Amyotrophic Lateral Sclerosis, sponsored by Anelixis Therapeutics, LLC. Completed at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-28.

Sponsored by Anelixis Therapeutics, LLC · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Enrollment
114th of 307
54 · median 33
Started
2020
with 28 others
Phase 2
89 of 440
8 open now
Registered
261st of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 114th largest by enrollment of the 307 interventional ones that give a count, is one of 29 that started in 2020, is one of 89 in phase 2, and was the 261st registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40 ligand (CD40L). Approximately 54 adults with Amyotrophic Lateral Sclerosis (ALS) will be enrolled into the study in the United States and Canada at approximately 13 ALS treatment sites.

Participants will be enrolled into one of four ascending doses.

Read the detailed description

This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40L. Approximately 54 adults with ALS will be enrolled into the study in the United States and Canada at approximately 13 ALS treatment sites.

Four ascending doses of AT-1501 will be administered as an IV infusion to sequentially enrolling cohorts. Each participant will receive 6 bi-weekly (every other week) infusions of AT-1501 over an 11-week period.

The study is estimated to take 19 weeks for participants.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • ALS
  • Lou Gehrig's Disease
  • motor neuron disease
  • motor neuron degeneration
  • AT-1501
  • humanized blocking antibody to CD40LG
  • CD40L inhibitor
  • monoclonal antibody
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ALS diagnosed as possible, laboratory supported probable, probable, or definite as defined by revised El Escorial criteria
  2. ALS Functional Rating Scale - Revised (ALSFRS-R) Aggregate score of 37 or greater
  3. No more than 24 months from diagnosis

Exclusion criteria

Exclusion Criteria:

  1. Any other central or peripheral nervous system disease that may interfere with the evaluation of ALS or its progression
  2. Presence of a tracheostomy, or use of permanent assistive ventilation (ventilatory support for 23 hours per day or more)
  3. History of within the previous 5 years, except for localized non-melanoma skin cancers
  4. Abnormal function of the immune system resulting from:

    • Clinical conditions affecting the immune system (e.g. infection, agammaglobulinemia),
    • Systemic administration of (PO/IV/IM) at a dose equivalent to 20 mg/day of prednisone for more than 14 consecutive days within 90 days prior to screening,
    • Administration of anti-neoplastic and/or immunomodulating agents (e.g. Tumor necrosis factor alpha (TNF α) antagonists or anti-B cell antibodies) or radiotherapy within 1 year prior to screening.
  5. Recipient of Stem Cell or Gene Therapy
  6. Positive test for surface antigen, antibody, or HIV.
  7. History of deep venous thrombosis or pulmonary embolism
  8. History of active substance abuse within the past 2 years
  9. History of stroke, poorly controlled or significant cardiovascular disease, diabetes
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    AT-1501

    4 sequential dose cohorts

    Drug: AT-1501

Interventions

  • AT-1501 monoclonal antibody targeting CD40L given as an IV infusion

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    Incidence of adverse events (AEs) reported as number of participants with at least one TEAE (Treatment Emergent Adverse Event) and at least one SAE (Serious Adverse Event).

    Time frame: Up to 18 Weeks

  2. Safety and Tolerability

    Incidence of adverse events (AEs) reported as number of TEAEs (Treatment Emergent Adverse Events) having occurred.

    Time frame: Up to 18 Weeks

07

Results

Posted Jun 28, 2023

Participant flow

Participant flow — Overall Study
MilestoneAT-1501 1.0 mg/kgAT-1501 2.0 mg/kgAT-1501 4.0 mg/kgAT-1501 8.0 mg/kg
Started991818
Completed871816
Not completed1202
Withdrew: Adverse event1100
Withdrew: Withdrawal by subject0002
Withdrew: Undergoing cancer treatment & was unable to return to site to complete eos visit within window0100

Outcome measures

PrimarySafety and Tolerability

Incidence of adverse events (AEs) reported as number of participants with at least one TEAE (Treatment Emergent Adverse Event) and at least one SAE (Serious Adverse Event).

Time frame:
Up to 18 Weeks
Reported as:
Number · participants
Safety and Tolerability
participantsAT-1501 1.0 mg/kgAT-1501 2.0 mg/kgAT-1501 4.0 mg/kgAT-1501 8.0 mg/kg
Number of Subjects with at Least One TEAE881016
Number of Subjects with at Least One SAE0100
PrimarySafety and Tolerability

Incidence of adverse events (AEs) reported as number of TEAEs (Treatment Emergent Adverse Events) having occurred.

Time frame:
Up to 18 Weeks
Reported as:
Number · TEAEs
Safety and Tolerability
TEAEsAT-1501 1.0 mg/kgAT-1501 2.0 mg/kgAT-1501 4.0 mg/kgAT-1501 8.0 mg/kg
Safety and Tolerability30665467

Adverse events

Collected over All serious adverse events were collected from the time of informed consent to 4 weeks after a patient's last dose of investigational product. All adverse events were collected from the first administration of investigational product until completion of the final visit, up to 15 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AT-1501 1.0 mg/kg0/9 (0%)0/9 (0%)8/9 (88.9%)
AT-1501 2.0 mg/kg0/9 (0%)1/9 (11.1%)8/9 (88.9%)
AT-1501 4.0 mg/kg0/18 (0%)0/18 (0%)10/18 (55.6%)
AT-1501 8.0 mg/kg0/18 (0%)0/18 (0%)16/18 (88.9%)
Most frequent serious events
Most frequent serious events
EventAT-1501 1.0 mg/kgAT-1501 2.0 mg/kgAT-1501 4.0 mg/kgAT-1501 8.0 mg/kg
Tonsil cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/91/90/180/18
Most frequent other events
Showing 10 of 101
Most frequent other events
EventAT-1501 1.0 mg/kgAT-1501 2.0 mg/kgAT-1501 4.0 mg/kgAT-1501 8.0 mg/kg
FatigueGeneral disorders4/93/90/187/18
HeadacheNervous system disorders3/92/93/183/18
FallInjury, poisoning and procedural complications0/93/95/184/18
DizzinessNervous system disorders2/91/91/181/18
HypoaesthesiaNervous system disorders1/92/90/180/18
Peripheral swellingGeneral disorders0/92/90/180/18
Muscle spasmsMusculoskeletal and connective tissue disorders2/92/90/182/18
Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders2/91/90/180/18
Neck painMusculoskeletal and connective tissue disorders1/92/90/180/18
DepressionPsychiatric disorders2/91/90/181/18

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)AT-1501 1.0 mg/kgAT-1501 2.0 mg/kgAT-1501 4.0 mg/kgAT-1501 8.0 mg/kgTotal
<=18 years00000
Between 18 and 65 years76151139
>=65 years233715
Age, Continuous
Age, Continuous(years)AT-1501 1.0 mg/kgAT-1501 2.0 mg/kgAT-1501 4.0 mg/kgAT-1501 8.0 mg/kgTotal
Mean61.2 ± 6.559 ± 14.7656.4 ± 8.5360.3 ± 11.1159 ± 10.29
Sex: Female, Male
Sex: Female, Male(Participants)AT-1501 1.0 mg/kgAT-1501 2.0 mg/kgAT-1501 4.0 mg/kgAT-1501 8.0 mg/kgTotal
Female326819
Male67121035
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AT-1501 1.0 mg/kgAT-1501 2.0 mg/kgAT-1501 4.0 mg/kgAT-1501 8.0 mg/kgTotal
Hispanic or Latino00033
Not Hispanic or Latino99181551
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AT-1501 1.0 mg/kgAT-1501 2.0 mg/kgAT-1501 4.0 mg/kgAT-1501 8.0 mg/kgTotal
American Indian or Alaska Native00000
Asian01102
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White98171852
More than one race00000
Unknown or Not Reported00000
ALSFRS-R Total Score at Screening
ALSFRS-R Total Score at Screening(units on a scale)AT-1501 1.0 mg/kgAT-1501 2.0 mg/kgAT-1501 4.0 mg/kgAT-1501 8.0 mg/kgTotal
Mean41.1 ± 3.0240.2 ± 1.9239.7 ± 3.6939.2 ± 2.6539.9 ± 3.0
ALSFRS-R Subdomain at Screening
ALSFRS-R Subdomain at Screening(units on a scale)AT-1501 1.0 mg/kgAT-1501 2.0 mg/kgAT-1501 4.0 mg/kgAT-1501 8.0 mg/kgTotal
Dyspnea4 ± 03.8 ± 0.443.7 ± 0.593.8 ± 0.433.8 ± 0.46
Orthopnea4.0 ± 03.8 ± 0.673.9 ± 0.323.9 ± 0.243.9 ± 0.35
Respiratory Insufficiency4.0 ± 04.0 ± 03.9 ± 0.473.7 ± 0.573.9 ± 0.44
ALSFRS-R Total Score at Baseline
ALSFRS-R Total Score at Baseline(units on a scale)AT-1501 1.0 mg/kgAT-1501 2.0 mg/kgAT-1501 4.0 mg/kgAT-1501 8.0 mg/kgTotal
Mean40.4 ± 3.1740.0 ± 2.039.6 ± 3.9938.6 ± 3.9639.5 ± 3.56

3 further baseline measures are reported on the registry.

08

Study locations

13 sites
  • Barrows Neurological Institute
    Phoenix, Arizona 85013, United States
  • University of California Irvine
    Orange, California 92868, United States
  • California Pacific Medical Center
    San Francisco, California 94109, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • University of Indiana
    Indianapolis, Indiana 46202, United States
  • The University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Johns Hopkins University Medical Center
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Hospital for Special Surgery (HSS)
    New York, New York 10021, United States
  • Providence Brain & Spine Institute
    Portland, Oregon 97213, United States
  • Texas Neurology, P.A.
    Dallas, Texas 75206, United States
  • Houston Methodist Neurological Institute
    Houston, Texas 77030, United States
  • Montreal Neurological Institute and Hospital
    Montreal, H3A 2B4, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Mar 2022, 17 months.

Results were first posted in Jun 2023, 1 year 3 months after primary completion.

Of 36 industry-sponsored phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 17 months is below that.

Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2020
First posted
Mar 26, 2020
StartActual
Oct 16, 2020
Primary completionActual
Mar 24, 2022
CompletionActual
Mar 24, 2022
Results first posted
Jun 28, 2023
Last update
Jun 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04322149
Lead sponsor
Anelixis Therapeutics, LLC
Responsible party
Sponsor
First posted
Mar 26, 2020
Start date
Oct 16, 2020
Primary completion
Mar 24, 2022
Completion
Mar 24, 2022
Results posted
Jun 28, 2023
Last update
Jun 28, 2023

Study contacts

Jeff Bornstein, MD
study chair · Eledon Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprubart

Start the discussion